Literature DB >> 17479231

Combined effect of mutations of the GH1 gene and its proximal promoter region in a child with growth hormone neurosecretory dysfunction (GHND).

Andrea Paola Rojas-Gil1, Panos G Ziros, Efthymios Kanetsis, Vassiliki Papathanassopoulou, Nikoleta M Nikolakopoulou, Kai He, Stuart J Frank, Athanasios G Papavassiliou, Bessie E Spiliotis.   

Abstract

Mutational analysis of the growth hormone 1 (GH1) gene and its promoter in a patient with GH neurosecretory dysfunction (GHND) revealed a heterozygous new deletion of one base 7-bp downstream from the 3'-splice site of exon 4 (IVS4'del+7) of the GH1 gene and two new heterozygous mutations at sites -135 and -138 of the GH1 promoter. In addition, two polymorphisms at sites -301 and -308 of the GH1 promoter were observed. All other family members had either the -301/-308 polymorphisms or the IVS4'del+7 mutation, but none had both. The IVS4'del+7 mutation located close to the splice donor site possibly interferes with the success of the splicing process, or the mutant transcripts are highly unstable because of nonsense-mediated mRNA decay. The -135/-138 mutations, albeit in close proximity to a putative Pit-1 recognition site, do not seem to affect binding of this transcription factor. The combination of the two polymorphisms, -301/-308, results in significantly reduced DNA-binding activity as monitored by electrophoretic mobility-shift assay. Transcription factor recognition site analysis of the GH1 promoter (MatInspector) revealed that HES1, one of the effectors of the Notch signalling system, is the only transcription factor whose binding is expected to be disrupted by each haplotype or by their combination. We provide evidence that the combination of -301/-308 polymorphisms with the IVS4'del+7 mutation in a GHND patient probably accounts for the reduced amount of growth hormone spontaneously secreted from his pituitary gland and for the severe growth delay.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17479231     DOI: 10.1007/s00109-007-0200-7

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  38 in total

1.  Alternative ribonucleic acid processing in endocrine systems.

Authors:  H Lou; R F Gagel
Journal:  Endocr Rev       Date:  2001-04       Impact factor: 19.871

2.  Biologically inactive growth hormone caused by an amino acid substitution.

Authors:  Y Takahashi; H Shirono; O Arisaka; K Takahashi; T Yagi; J Koga; H Kaji; Y Okimura; H Abe; T Tanaka; K Chihara
Journal:  J Clin Invest       Date:  1997-09-01       Impact factor: 14.808

Review 3.  Nonsense-mediated RNA decay: a molecular system micromanaging individual gene activities and suppressing genomic noise.

Authors:  Claudio R Alonso
Journal:  Bioessays       Date:  2005-05       Impact factor: 4.345

4.  A novel mutation at the donor splice site of intron 3 of the GH-I gene in a patient with isolated growth hormone deficiency.

Authors:  Y Hayashi; T Kamijo; M Yamamoto; S Ohmori; J A Phillips; M Ogawa; Y Igarashi; H Seo
Journal:  Growth Horm IGF Res       Date:  1999-12       Impact factor: 2.372

5.  Two different 5' splice site mutations in the growth hormone gene causing autosomal dominant growth hormone deficiency.

Authors:  C Missarelli; L Herrera; V Mericq; P Carvallo
Journal:  Hum Genet       Date:  1997-11       Impact factor: 4.132

6.  The notch signaling system is present in the postnatal pituitary: marked expression and regulatory activity in the newly discovered side population.

Authors:  Jianghai Chen; Annelies Crabbe; Vik Van Duppen; Hugo Vankelecom
Journal:  Mol Endocrinol       Date:  2006-09-07

7.  Growth hormone (GH) provocative testing frequently does not reflect endogenous GH secretion.

Authors:  B B Bercu; D Shulman; A W Root; B E Spiliotis
Journal:  J Clin Endocrinol Metab       Date:  1986-09       Impact factor: 5.958

Review 8.  Genesis of episodic growth hormone secretion.

Authors:  G S Tannenbaum
Journal:  J Pediatr Endocrinol       Date:  1993 Jul-Dec

9.  A recurring dominant negative mutation causes autosomal dominant growth hormone deficiency--a clinical research center study.

Authors:  J D Cogan; B Ramel; M Lehto; J Phillips; M Prince; R M Blizzard; T J de Ravel; M Brammert; L Groop
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

10.  Signalling downstream of activated mammalian Notch.

Authors:  S Jarriault; C Brou; F Logeat; E H Schroeter; R Kopan; A Israel
Journal:  Nature       Date:  1995-09-28       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.